<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797649</url>
  </required_header>
  <id_info>
    <org_study_id>NTProBNPPleuralEffusion1</org_study_id>
    <nct_id>NCT05797649</nct_id>
  </id_info>
  <brief_title>Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis</brief_title>
  <official_title>Comparing N-terminal-proB-type Natriuretic Peptide With Other Diagnostic Criteria in Discriminating Heart Failure-associated From Non-heart Failure-associated Pleural Effusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the discriminative properties of pleural fluid (PF)&#xD;
      N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure&#xD;
      (HF)-associated pleural effusions (PE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the discriminative properties of pleural fluid (PF)&#xD;
      N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure&#xD;
      (HF)-associated pleural effusions (PE).&#xD;
&#xD;
      Hypothesis to be tested: The PF NTproBNP levels are superior to existing methods including&#xD;
      Light's criteria, serum/pleural fluid (S/PF) protein gradient, and albumin gradient, in&#xD;
      identifying transudates and distinguishing between HF- and non-HF-associated PE.&#xD;
&#xD;
      Design and subjects: A prospective case-control study involving patients with PE requiring&#xD;
      thoracentesis, caused by hypervolaemia due to HF, diseases other than HF, and patients with&#xD;
      pleural effusion without hypervolaemia. Patient characteristics, PF results and effusion&#xD;
      aetiology will be analysed. Patient outcomes will be followed up to 3 months to confirm the&#xD;
      aetiology of PE. Clinical management of patients will not be affected.&#xD;
&#xD;
      Study instruments: PF of recruited patients will be analysed for albumin, protein, lactate&#xD;
      dehydrogenase (LDH) levels and NTproBNP. The diagnosis of HF will be based on clinical&#xD;
      features, serum NTproBNP and echocardiogram.&#xD;
&#xD;
      Main outcome measures: The performance of PF NTproBNP level in identifying HF-associated PE.&#xD;
&#xD;
      Data analysis: The PF NTproBNP level will be compared between effusions of different&#xD;
      aetiologies. The optimal pleural fluid NTproBNP level with largest area under the receiver&#xD;
      operating characteristic curve in identifying HF-associated PE will be determined.&#xD;
      Performance of PF NTproBNP level in identifying HF-associated PE, and other biochemical&#xD;
      criteria in identifying transudates will be compared. Echocardiographic findings will be&#xD;
      correlated with the PF NTproBNP levels.&#xD;
&#xD;
      Expected results: The diagnostic performance of PF NTproBNP will be significantly better in&#xD;
      identifying HF-associated effusion than other biochemical criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2023</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Comparison of the diagnostic performance of PF NTproBNP level in the diagnosis of HF-associated pleural effusions with other conventional biochemical criteria</measure>
    <time_frame>24 months</time_frame>
    <description>Pleural fluid NTproBNP will be measured in patients with pleural effusion of various aetiologies including malignancy, pleural infection, heart failure and other causes of volume overload. The sensitivity and specificity of an elevated pleural fluid NTproBNP level in successfully identifying a pleural effusion due to underlying heart failure will be measured and compared against existing classification criteria for pleural effusion such as Light's Criteria, pleural-serum protein gradient or albumin gradient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the PF NTproBNP level in patients with pleural effusion of various aetiologies</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of clinical factors that may affect the levels of pleural fluid NTproBNP such as echocardiographic features, presence of comorbidities, nutritional status, serum albumin level, levels of inflammatory markers and presence of infection</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical data of patients admitted to the hospital with pleural effusion will be measured and recorded. Statistical analysis will then be performed to evaluate for degree of correlation between the presence or severity of a clinical parameter, echocardiogram results e.g. severe valvular stenosis, or, e.g. presence of medical comorbidities or presence of concomitant infection, and the levels of NTproBNP identified in the patient's pleural fluid detected within same admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the PF NTproBNP levels with the echocardiographic features and prognosis of patients with heart failure</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pleural Effusion</condition>
  <condition>Heart Failure</condition>
  <condition>Malignant Neoplasm</condition>
  <condition>Fluid Overload</condition>
  <condition>Hypoalbuminemia</condition>
  <condition>Renal Failure</condition>
  <condition>Cirrhosis</condition>
  <condition>Infections</condition>
  <arm_group>
    <arm_group_label>Heart Failure-Associated Pleural Effusion</arm_group_label>
    <description>Patients with pleural effusion with an underlying aetiology of heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Heart Failure, Fluid Overload-Associated Pleural Effusion</arm_group_label>
    <description>Patients with pleural effusion with an underlying aetiology of fluid overload excluding heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with pleural effusion due to exudative, or non-fluid overload causes</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pleural Fluid and Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are admitted to the Department of Medicine &amp; Therapeutics, Prince of Wales&#xD;
        Hospital (PWH) who fulfil the inclusion and exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients hospitalized for heart failure and pleural effusion&#xD;
&#xD;
          -  Pleural tapping indicated for pleural fluid analysis.&#xD;
&#xD;
          -  Aged 18 years old or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral&#xD;
             pleural space.&#xD;
&#xD;
          -  History of surgical decortication or pleurodesis in the ipsilateral pleural space.&#xD;
&#xD;
          -  Ipsilateral thoracic or cardiac surgery in the past 3 months.&#xD;
&#xD;
          -  Failure to obtain informed consent due to the patient's refusal or cognitive&#xD;
             impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Chan, MBChB</last_name>
    <phone>35053396</phone>
    <email>christopherchan@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ken KP Chan, MBChB</last_name>
    <phone>35053396</phone>
    <email>chankapang@cuhk.edu.hk</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 16, 2023</study_first_submitted>
  <study_first_submitted_qc>March 31, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 31, 2023</last_update_submitted>
  <last_update_submitted_qc>March 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Christopher Chan</investigator_full_name>
    <investigator_title>Honorary Clinical Tutor</investigator_title>
  </responsible_party>
  <keyword>pleural fluid</keyword>
  <keyword>heart failure</keyword>
  <keyword>malignancy</keyword>
  <keyword>cancer</keyword>
  <keyword>echocardiography</keyword>
  <keyword>infection</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>respiratory medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypoalbuminemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Given patient data and privacy concerns, clinical data involving individual patients will not be shared. Data summary tables may later be published along with the research manuscript, and may be shared upon receipt of a reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

